Live Analyst Rating Changes 23961 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Mark Massaro
BTIG

Mark Massaro

Wall Street Analyst
★★★★★
#118
on 13Foresight · ranked by our own returns
67%
Success Rate
+21.8%
Average Return
37 of 55 calls profitable · +16.5% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 67% of Mark Massaro's ratings turned a profit when each position was held for 1 year — averaging +21.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

94 Buy 22 Hold 2 Sell
Mark's Stock Coverage 36 ratings · 2026-08-13
Company Date Position Consensus Price Target 1-Yr Return vs S&P 500
TKNO
Alpha Teknova
Aug 11, 2026 BUY Strong Buy
+81.2% avg upside
7 analysts
$8.00
8.33% Upside
+0.0% ·
CAI
Caris Life Sciences, Inc.
Aug 07, 2026 BUY Strong Buy
+24.7% avg upside
20 analysts
$33.00
48.24% Upside
-1.6% ·
NTRA
Natera
Aug 07, 2026 BUY Strong Buy
-3.4% avg upside
27 analysts
$320.00
1.32% Upside
-3.5% ·
CDNA
CareDx
Aug 06, 2026 BUY Buy
-14.6% avg upside
17 analysts
$60.00
26.88% Upside
+3.9% ·
BLLN
BillionToOne, Inc. Class A
Aug 06, 2026 BUY Strong Buy
+25.6% avg upside
9 analysts
$130.00
33.35% Upside
+2.6% ·
XGN
Exagen
Aug 05, 2026 BUY Strong Buy
+91.6% avg upside
10 analysts
$9.00
36.55% Upside
+3.3% ·
SOPH
SOPHiA GENETICS
Aug 05, 2026 BUY Strong Buy
+38.8% avg upside
8 analysts
$9.00
18.97% Upside
+21.6% ·
WGS
GeneDx Holdings
Aug 04, 2026 BUY Strong Buy
-2.0% avg upside
9 analysts
$90.00
9.21% Upside
+11.0% ·
TEM
Tempus AI, Inc. Class A
Aug 03, 2026 BUY Buy
+19.4% avg upside
21 analysts
$70.00
28.11% Upside
+17.9% ·
CSTL
Castle Biosciences
Aug 03, 2026 BUY Strong Buy
+31.2% avg upside
9 analysts
$44.00
39.94% Upside
+3.4% ·
GH
Guardant Health
Jul 31, 2026 BUY Strong Buy
-0.7% avg upside
31 analysts
$195.00
18.09% Upside
-0.8% ·
ADPT
Adaptive Biotechnologies
Jul 30, 2026 BUY Strong Buy
-5.6% avg upside
15 analysts
$25.00
0.92% Downside
+2.7% ·
NEO
NeoGenomics
Jul 28, 2026 HOLD Strong Buy
+4.6% avg upside
18 analysts
+23.0% ·
PSNL
Personalis
Jul 20, 2026 BUY Strong Buy
+3.9% avg upside
11 analysts
$16.25
14.42% Upside
+5.1% ·
LUCD
Lucid Diagnostics
May 15, 2026 BUY Strong Buy
+391.2% avg upside
8 analysts
$2.50
153.96% Upside
-1.0% ·
IMDX
Insight Molecular Diagnostics
May 15, 2026 HOLD Buy
+21.3% avg upside
10 analysts
-24.6% ·
MXCT
MaxCyte
May 13, 2026 HOLD Buy
+214.9% avg upside
5 analysts
+36.3% ·
MDXH
MDxHealth
May 13, 2026 BUY Strong Buy
+1251.3% avg upside
8 analysts
$4.00
751.75% Upside
-76.4% ·
CERS
Cerus
May 01, 2026 BUY Strong Buy
+102.2% avg upside
10 analysts
$4.00
47.62% Upside
-0.4% ·
DNA
Ginkgo Bioworks Holdings
Mar 12, 2026 SELL Strong Sell
-2.6% avg upside
6 analysts
$5.00
30.73% Downside
-13.1% ·
ZTS
Zoetis
Feb 26, 2026 BUY Buy
+62.6% avg upside
23 analysts
$160.00
117.54% Upside
-40.9% ·
IDXX
Idexx Laboratories
Feb 03, 2026 BUY Buy
+26.1% avg upside
17 analysts
$800.00
40.19% Upside
-9.8% ·
BNGO
BioNano Genomics
Aug 22, 2025 HOLD Buy
+693.0% avg upside
9 analysts
-70.0% ·
RNLXY
Renalytix
May 20, 2024 BUY Strong Buy
+283.4% avg upside
5 analysts
$2.00
28.63% Downside
· ·
HLTHQ
Cue Health
Mar 21, 2024 HOLD Hold
2 analysts
· ·
TTOO
T2 Biosystems
Sep 22, 2023 HOLD Buy
+1421150.0% avg upside
10 analysts
· ·
HTGMQ
HTG Molecular Diagnostics
Dec 06, 2019 HOLD Strong Buy
+733333233.4% avg upside
6 analysts
· ·
QDEL
QuidelOrtho
Nov 17, 2019 BUY Buy
+165.7% avg upside
13 analysts
$75.00
405.66% Upside
+201.7% ·
OSUR
Orasure Technologies
Nov 10, 2019 HOLD Buy
+124.9% avg upside
11 analysts
$8.00
113.23% Upside
+54.8% ·
QTRX
Quanterix
Nov 06, 2019 BUY Buy
+554.5% avg upside
8 analysts
$35.00
1094.48% Upside
+157.7% ·
LH
Labcorp Holdings
Oct 24, 2019 HOLD Strong Buy
-16.0% avg upside
37 analysts
$170.00
47.39% Downside
+26.3% ·
ILMN
Illumina
Oct 24, 2019 HOLD Buy
-8.8% avg upside
31 analysts
$310.00
60.75% Upside
+2.5% ·
DGX
Quest Diagnostics
Oct 22, 2019 BUY Buy
-22.8% avg upside
34 analysts
$113.00
52.38% Downside
+28.2% ·
AWHL
Aspira Women's Health
May 23, 2018 HOLD Strong Buy
+1256.8% avg upside
6 analysts
$1.00
151.35% Upside
· ·
RIOT
Riot Platforms
Feb 09, 2016 HOLD Strong Buy
+51.1% avg upside
29 analysts
$4.00
80.28% Downside
· ·
BDX
Becton Dickinson
May 07, 2015 HOLD Buy
+7.4% avg upside
25 analysts
$145.00
21.04% Downside
+17.5% ·
🔒 31 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Mark Massaro — Frequently Asked Questions
How accurate are Mark Massaro's stock ratings?
Based on the calls 13Foresight could measure, about 69% of Mark's ratings were profitable over a one-year hold, with an average return of +21.6% per rating, or +16.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Mark ranked on 13Foresight?
Mark Massaro is currently ranked #118 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Mark cover?
Mark most recently has ratings on TKNO, CAI, NTRA, CDNA, BLLN, XGN, SOPH, WGS, TEM, CSTL, GH, ADPT and 24 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.